Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Fischer

Showing results (451-460 of 490) with videos related to

Pageof 49
Sort By:
Blood|September 10, 2005
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domainFlorian Heidel, Fian K Solem, Frank Breitenbuecher, et al.
Pediatric Allergy, Immunology, and Pulmonology|July 7, 2012
The Greater Cincinnati Pediatric Clinic Repository: A Novel Framework for Childhood Asthma and Allergy ResearchMelinda Butsch Kovacic, Jocelyn M Biagini Myers, Mark Lindsey, et al.
Psychoneuroendocrinology|March 18, 2022
Interleukin-18 signaling system links to agitation in severe mental disordersGabriela Hjell, Attila Szabo, Lynn Mørch-Johnsen, et al.
Blood|August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupWolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.
Journal of Hematology & Oncology|June 9, 2024
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasiaTobias Ronny Haage, Emmanouil Charakopoulos, Vikas Bhuria, et al.
Haematologica|April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalJesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
Annals of Hematology|September 16, 2021
Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trialsThomas Heinicke, Rainer Krahl, Christoph Kahl, et al.
Annals of Hematology|July 7, 2021
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trialsThomas Heinicke, Rainer Krahl, Christoph Kahl, et al.
BMC Psychiatry|September 6, 2023
Impulsivity across severe mental disorders: a cross-sectional study of immune markers and psychopharmacotherapyGabriela Hjell, Jaroslav Rokicki, Attila Szabo, et al.
BMC Medicine|October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<sup>+</sup> breast cancerPhilipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Pageof 49

Showing results (451-460 of 490) with videos related to

Sort By:
Pageof 49
Blood|September 10, 2005
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domainFlorian Heidel, Fian K Solem, Frank Breitenbuecher, et al.
Pediatric Allergy, Immunology, and Pulmonology|July 7, 2012
The Greater Cincinnati Pediatric Clinic Repository: A Novel Framework for Childhood Asthma and Allergy ResearchMelinda Butsch Kovacic, Jocelyn M Biagini Myers, Mark Lindsey, et al.
Psychoneuroendocrinology|March 18, 2022
Interleukin-18 signaling system links to agitation in severe mental disordersGabriela Hjell, Attila Szabo, Lynn Mørch-Johnsen, et al.
Blood|August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupWolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.
Journal of Hematology & Oncology|June 9, 2024
Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasiaTobias Ronny Haage, Emmanouil Charakopoulos, Vikas Bhuria, et al.
Haematologica|April 6, 2023
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survivalJesse M Tettero, Lok Lam Ngai, Costa Bachas, et al.
Annals of Hematology|September 16, 2021
Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trialsThomas Heinicke, Rainer Krahl, Christoph Kahl, et al.
Annals of Hematology|July 7, 2021
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trialsThomas Heinicke, Rainer Krahl, Christoph Kahl, et al.
BMC Psychiatry|September 6, 2023
Impulsivity across severe mental disorders: a cross-sectional study of immune markers and psychopharmacotherapyGabriela Hjell, Jaroslav Rokicki, Attila Szabo, et al.
BMC Medicine|October 8, 2024
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER<sup>+</sup> breast cancerPhilipp Zimmer, Tobias Esser, Diana Lueftner, et al.
Pageof 49